The US Food and Drug Administration on Thursday announced two revised doses per vial for the Moderna COVID-19 Vaccine to positively impact the supply of the vaccine to provide more vaccine doses to communities.
According to the agency, the first revision clarifies the number of doses per vial for the vials that are currently available, in that the maximum number of extractable doses is 11, with a range of 10-11 doses. The second revision authorizes the availability of an additional multi-dose vial in which each vial contains a maximum of 15 doses, with a range of 13-15 doses that can potentially be extracted.
Based on the type of syringes and needles used to extract each dose, there may not be sufficient volume to extract more than 10 doses from the vial containing a maximum of 11 doses or more than 13 doses from the vial containing a maximum of 15 doses. However, the dosing regimen remains unchanged. The vaccine is administered as a two-dose series, 0.5 ml each dose, one month apart, added the agency.
In conjunction, the Fact Sheet for Healthcare Providers Administering Vaccine and Prescribing Information have been revised to reflect the new information to help frontline workers administering COVID-19 vaccines understand the number of doses that can be extracted per vial, concluded the agency.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid